Sunflower Pharmaceuticals Group Co Ltd - Asset Resilience Ratio
Sunflower Pharmaceuticals Group Co Ltd (002737) has an Asset Resilience Ratio of 29.28% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 002737 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Sunflower Pharmaceuticals Group Co Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Sunflower Pharmaceuticals Group Co Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sunflower Pharmaceuticals Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002737 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.50 Billion | 29.28% |
| Total Liquid Assets | CN¥1.50 Billion | 29.28% |
Asset Resilience Insights
- Very High Liquidity: Sunflower Pharmaceuticals Group Co Ltd maintains exceptional liquid asset reserves at 29.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sunflower Pharmaceuticals Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sunflower Pharmaceuticals Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Sunflower Pharmaceuticals Group Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Sunflower Pharmaceuticals Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.60% | CN¥1.26 Billion ≈ $184.12 Million |
CN¥5.83 Billion ≈ $852.51 Million |
+2.49pp |
| 2023-12-31 | 19.11% | CN¥1.32 Billion ≈ $192.44 Million |
CN¥6.88 Billion ≈ $1.01 Billion |
-1.49pp |
| 2022-12-31 | 20.60% | CN¥1.45 Billion ≈ $211.99 Million |
CN¥7.03 Billion ≈ $1.03 Billion |
+8.74pp |
| 2021-12-31 | 11.87% | CN¥668.69 Million ≈ $97.85 Million |
CN¥5.64 Billion ≈ $824.61 Million |
+8.92pp |
| 2020-12-31 | 2.94% | CN¥150.49 Million ≈ $22.02 Million |
CN¥5.11 Billion ≈ $748.24 Million |
-0.92pp |
| 2019-12-31 | 3.86% | CN¥205.00 Million ≈ $30.00 Million |
CN¥5.31 Billion ≈ $776.92 Million |
-0.95pp |
| 2018-12-31 | 4.81% | CN¥243.46 Million ≈ $35.63 Million |
CN¥5.06 Billion ≈ $740.31 Million |
-0.87pp |
| 2017-12-31 | 5.68% | CN¥254.00 Million ≈ $37.17 Million |
CN¥4.47 Billion ≈ $654.13 Million |
-0.43pp |
| 2016-12-31 | 6.11% | CN¥258.00 Million ≈ $37.75 Million |
CN¥4.22 Billion ≈ $618.05 Million |
-- |
About Sunflower Pharmaceuticals Group Co Ltd
Sunflower Pharmaceutical Group Co.,Ltd engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally. The company produces chemical and biological medicines, and health care products. It also provides products covering various therapeutic areas, including pediatrics, gynecology, adult digestive system, respiratory and cold, rheumati… Read more